Literature DB >> 21166097

Hepatitis B and C virus infections in hepatocellular carcinoma and cirrhosis in Mongolia.

Bolormaa Dondog1, Mauro Lise, Oyunchimeg Dondov, Baigal Baldandorj, Silvia Franceschi.   

Abstract

The incidence of hepatocellular carcinoma (HCC) in Mongolia is far higher than that of any other cancer in the country, and among the highest worldwide. The relative importance of infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) is unclear. We reviewed (i) medical records for 963 patients with HCC and 941 patients with cirrhosis admitted for the first time to the National Cancer Center of Mongolia and the National Center for Communicable Diseases, respectively, from 2000 to 2009,and (ii) articles published from 1990 to 2010 on the seroprevalence of hepatitis B surface antigen (HBsAg) and antibodies against hepatitis C virus (anti-HCV) among individuals with and without liver disease. Among those with HCC, the seroprevalence of HBsAg, anti-HCV and dual infections was 50, 27 and 21%, respectively. Corresponding percentages among the patients with cirrhosis were 40, 39, and 20%. In both diseases, HCV infection was relatively more prevalent in women than in men and, in cirrhosis, inpatients older than 45 years of age. In healthy individuals,from published articles, anti-HCV seroprevalence steadily increased with age (from 3% at age 0-5 years to 34% at age ≥ 50 years), whereas HBsAg seroprevalence stayed constant at about 8%. The future benefit of childhood vaccination against HBV in Mongolia will be undermined by the consequences of a severe HCV epidemic and a uniquely high burden of dual infections.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21166097     DOI: 10.1097/cej.0b013e32833f0c8e

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  10 in total

1.  Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents.

Authors:  Laura Torrens; Marc Puigvehí; Miguel Torres-Martín; Huan Wang; Miho Maeda; Philipp K Haber; Thais Leonel; Mireia García-López; Roger Esteban-Fabró; Wei Qiang Leow; Carla Montironi; Sara Torrecilla; Ajay Ramakrishnan Varadarajan; Patricia Taik; Genís Campreciós; Chinbold Enkhbold; Erdenebileg Taivanbaatar; Amankyeldi Yerbolat; Augusto Villanueva; Sofía Pérez-Del-Pulgar; Swan Thung; Jigjidsuren Chinburen; Eric Letouzé; Jessica Zucman-Rossi; Andrew Uzilov; Jaclyn Neely; Xavier Forns; Sasan Roayaie; Daniela Sia; Josep M Llovet
Journal:  Clin Cancer Res       Date:  2022-10-14       Impact factor: 13.801

2.  Hepatitis C virus seroprevalence in the general female population from 8 countries.

Authors:  Paloma Quesada; Denise Whitby; Yolanda Benavente; Wendell Miley; Nazzarena Labo; Saibua Chichareon; Nguyen Trong; Hai-Rim Shin; Pham Thi Hoang Anh; Jaiyeola Thomas; Elena Matos; Rolando Herrero; Nubia Muñoz; Monica Molano; Silvia Franceschi; Silvia de Sanjosé
Journal:  J Clin Virol       Date:  2015-05-12       Impact factor: 3.168

Review 3.  Status quo of chronic liver diseases, including hepatocellular carcinoma, in Mongolia.

Authors:  Amarsanaa Jazag; Natsagnyam Puntsagdulam; Jigjidsuren Chinburen
Journal:  Korean J Intern Med       Date:  2012-05-31       Impact factor: 2.884

Review 4.  Cancer control programs in East Asia: evidence from the international literature.

Authors:  Malcolm A Moore
Journal:  J Prev Med Public Health       Date:  2014-07-31

5.  Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia.

Authors:  Yoona A Kim; Jacqueline Estevez; An Le; Dennis Israelski; Oidov Baatarkhuu; Tserenchimed Sarantuya; Sonom Narantsetseg; Pagbajabyn Nymadawa; Richard H Le; Man-Fung Yuen; Geoffrey Dusheiko; Mario Rizzetto; Mindie H Nguyen
Journal:  BMJ Open Gastroenterol       Date:  2016-11-10

6.  Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L.

Authors:  Marina G Tarakanovskaya; Jigjidsuren Chinburen; Purev Batchuluun; Chogsom Munkhzaya; Genden Purevsuren; Dorjiin Dandii; Tsogkhuu Hulan; Dandii Oyungerel; Galyna A Kutsyna; Alan A Reid; Vika Borisova; Allen I Bain; Vichai Jirathitikal; Aldar S Bourinbaiar
Journal:  J Hepatocell Carcinoma       Date:  2017-04-12

7.  Mongolia health situation: based on the Global Burden of Disease Study 2019.

Authors:  Odgerel Chimed-Ochir; Vanya Delgermaa; Ken Takahashi; Oyuntsetseg Purev; Amarzaya Sarankhuu; Yoshihisa Fujino; Narantuya Bayarmagnai; Otgontuya Dugee; Ryenchindorj Erkhembayar; Battur Lkhagvaa; Chimedsuren Ochir; Tumenjavkhlan Sosorburam; Mohsen Naghavi
Journal:  BMC Public Health       Date:  2022-01-04       Impact factor: 3.295

8.  Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis.

Authors:  Ali A Mokdad; Alan D Lopez; Saied Shahraz; Rafael Lozano; Ali H Mokdad; Jeff Stanaway; Christopher J L Murray; Mohsen Naghavi
Journal:  BMC Med       Date:  2014-09-18       Impact factor: 8.775

Review 9.  Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia.

Authors:  Oidov Baatarkhuu; Tsagaantsooj Gerelchimeg; Dashchirev Munkh-Orshikh; Badamnachin Batsukh; Ganbold Sarangua; Jazag Amarsanaa
Journal:  Euroasian J Hepatogastroenterol       Date:  2018-05-01

10.  High Prevalence of Chronic Viral Hepatitis and Liver Fibrosis Among Mongols in Southern California.

Authors:  Tse-Ling Fong; Naranbaatar D Dashdorj; Takeshi Saito; Brian T Lee; Mimi Chang; Khishigsuren Nasanbayar; Enkhjargal Tsogtoo; Delgerbat Boldbaatar; Esugen D Dashdorj; Namuun E Clifford; Arghun N Dashdorj; Bo-Ram Bang; Takeshi Chida; Carolina Lim; Masaya Sugiyama; Masashi Mizokami; Naranjargal J Dashdorj; Ping Liu; Jeffrey S Glenn
Journal:  Dig Dis Sci       Date:  2020-08-08       Impact factor: 3.487

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.